Corticosteroid Therapy in Neonatal Septic Shock-Do We Prevent Death?

Area of Science:

• Neonatalogy
• Pediatric Critical Care
• Pharmacology

Background:

• Septic shock in premature neonates is a critical condition requiring intensive management.
• Hydrocortisone (HC) is sometimes used to improve hemodynamic stability in these patients.
• The impact of HC on both short-term and long-term outcomes remains an area of investigation.

Purpose of the Study:

• To compare the survival rates of premature neonates with septic shock who received hydrocortisone (HC) versus those who did not.
• To analyze the hemodynamic response to HC administration in this vulnerable population.
• To evaluate the long-term survival implications of HC use during septic shock.

Main Methods:

• A retrospective study involving 62 premature neonates diagnosed with septic shock and/or necrotizing enterocolitis (NEC) stage 2 or higher.
• Patients received inotropes, with some also receiving HC.
• Survival and hemodynamic parameters (e.g., blood pressure, urine output, vasoactive index score) were analyzed.

Main Results:

• Hydrocortisone administration led to significant improvements in blood pressure, urine output, and oxygen requirements, with a decreased vasoactive index score.
• Despite receiving more intensive support, neonates treated with HC had similar survival rates during the septic episode compared to those without HC.
• However, infants receiving HC showed significantly reduced survival at 1-year postmenstrual age follow-up, even after accounting for gestational age and inotrope duration.

Conclusions:

• Hydrocortisone (HC) effectively improved hemodynamic parameters in premature neonates with septic shock requiring inotropic support.
• While HC did not alter immediate survival from the septic episode, its use was associated with decreased survival at 1-year postmenstrual age.
• These findings suggest a potential long-term detrimental effect of HC in this patient population, warranting careful consideration.